Lynparza approved in China as a 1st- line maintenance therapy in BRCA-mutated advanced ovarian cancer. Only PARP inhibitor approved in this setting in China. The approval in China is based on the results from the Phase III SOLO-1 trial, which were published in The New England Journal of Medicine. Results showed that Lynparza significantly reduced the risk of...
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada. AstraZeneca has agreed to sell the commercial rights to Seroquel and Seroquel XR in the US and Canada to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and...
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. As at 30 November 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,913,268 ordinary shares of US $0.25. The above figure for the total number of voting rights may be used by shareholders as the...
RNS Number: 3770 V AstraZeneca PLC 02 December 2019 02 December 2019 15:00 GMT. Block Listing Six Monthly Return. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
The sBLA was based on positive results from the Phase III CASPIAN trial published in The Lancet, s howing Imfinzi in combination with standard-of-care chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival vs. Imfinzi is approved in the curative-intent setting of unresectable, Stage III...
AstraZeneca today announced that the US Food and Drug Administration has approved CALQUENCE ® for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The US approval was granted under the FDA’ s Real-Time Oncology Review and newly established Project Orbis programs. The approval is based on positive results from the interim...
RNS Number: 2853 U AstraZeneca PLC 21 November 2019 21 November 2019 18:10 GMT. Calquence approved in the US for adult patients with chronic lymphocytic leukaemia. Two Phase III Calquence trials demonstrated superior progression-free survival across multiple settings while maintaining favourable tolerability.
Roxana Mehran, TWILIGHT's Global Principal Investigator and Director of the Center for Interventional Cardiovascular Research and Clinical Trials at Mount Sinai Heart and Professor of Cardiology, and Population Health Science and Policy, at Icahn School of Medicine at Mount Sinai in New York, US, said:“ The finding that ticagrelor monotherapy was not...
AstraZeneca today announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that FARXIGA reduced the risk of the primary composite outcome of worsening heart failure, defined as hospitalization or an urgent visit, or death from cardiovascular causes versus placebo, when added to standard of care.
RNS Number: 5476 T AstraZeneca PLC 15 November 2019 15 November 2019 07:00 GMT. Qtrilmet approved in the EU f or the treatment of type-2 diabetes. AstraZeneca today announced that the European Commission has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes..
AstraZeneca today announced the launch of Diabetes Can Break Your Heart, a national movement with a goal to change the trajectory of heart failure in type 2 diabetes. The initiative is designed to raise awareness, create community action and spark dialogue between those with T2D and their healthcare providers to help reduce the risk of HF— one of the earliest...
RNS Number: 3486 T AstraZeneca PLC 14 November 2019 14 November 2019 07:00 GMT. US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review. AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that the US Food and Drug Administration has accepted a New Drug Application and granted Priority Review for...
RNS Number: 0408 T AstraZeneca PLC 12 November 2019 12 November 2019 07:00 GMT. Anifrolumab demonstrated superiority across multiple efficacy endpoints. in patients with systemic lupus erythematosus in Phase III TULIP 2 trial.
RNS Number: 8848 S AstraZeneca PLC 11 November 2019 11 November 2019 07:00 GMT. Roxadustat Phase III programme pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anaemia from chronic kidney disease. The results were presented in an oral late-breaking abstract session at the American Society of Nephrology...
AstraZeneca and FibroGen Inc. today presented pooled efficacy and cardiovascular safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease. The results were presented in an oral late-breaking abstract session at the American Society of Nephrology Kidney Week 2019 in...
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA ® for the treatment of heart failure. The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular death or worsening of HF in patients with HF with reduced...
RNS Number: 7220 S AstraZeneca PLC 08 November 2019 8 November 2019 07:00 GMT. Roxadustat significantly increased haemoglobin levels for chronic kidney disease patients with anaemia in Phase III OLYMPUS and ROCKIES trials. The results were presented today during two oral sessions at the American Society of Nephrology Kidney Week 2019 in Washington, D.C., US..
AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased hemoglobin levels in both non-dialysis-dependent and dialysis-dependent patients with anemia from chronic kidney disease, respectively. The results were presented today during two oral sessions at the...
AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing CALQUENCE ®, a next-generation selective Bruton’ s tyrosine kinase inhibitor, in patients with previously untreated chronic lymphocytic leukemia, as well as data from novel-combination trials across multiple blood cancers at the 2019 American Society of Hematology...
RNS Number: 5205 S AstraZeneca PLC 06 November 2019 6 November 2019 14:00 GMT. Calquence data to show improved progression-free survival in Phase III front-line chronic lymphocytic leukaemia trial at ASH 2019 Annual Meeting. AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing Calquence, a next-generation selective...
AstraZeneca Plc
AZN.L
AstraZeneca Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.27B

Company Profile

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Classification

Market Indices-

Locations

HQ
Cambridge Biomedical Campus
1 Francis Crick Avenue
Cambridge
CB2 0AA
Watchlist